UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION

Washington, D.C. 20549

SCHEDULE 13G/A

Under the Securities Exchange Act of 1934

(Amendment No. 2)*


Cytokinetics, Incorporated

(Name of Issuer)


Common Stock, par value $0.001 per share

(Title of Class of Securities)

 

23282W 10 0

(CUSIP Number)

 

December 31, 2006

(Date of Event Which Requires Filing of this Statement)

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

o Rule 13d-1(b)

o Rule 13d-1(c)

x Rule 13d-1(d)

 

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

 

 

 



 

 

CUSIP No. 23282W 10 0

 

1

NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

 


Credit Suisse

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 

 

 

 

 

(a)

o

 

 

 

 

 

 

 

 

(b)

x

 

 

 

 

 

 

3

SEC USE ONLY

4

CITIZENSHIP OR PLACE OF ORGANIZATION

 



SWITZERLAND

 

 

 



NUMBER OF

5

SOLE VOTING POWER

-0-

SHARES
BENEFICIALLY
OWNED BY
EACH

6

SHARED VOTING POWER

1,366,369

REPORTING
PERSON
WITH:

7

SOLE DISPOSITIVE POWER

-0-

 

8

SHARED DISPOSITIVE POWER

3,132,052

   

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

3,132,052

   

10

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [ ]

 

11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

7.2%

   

12

TYPE OF REPORTING PERSON

BK

 

 

 

 

 

 

 



Item 1.

 

   

(a)

Name of Issuer:

Cytokinetics, Incorporated

   

(b)

Address of Issuer's Principal Executive Offices:

280 East Grand Avenue, South San Francisco, California 94080

Item 2.

 

   

(a)

Name of Person Filing:

Credit Suisse. See Schedule I.

   

(b)

Address of Principal Business Office or, if none, Residence:

Uetlibergstrasse 231, P.O. Box 900, CH-8070 Zurich, Switzerland

   

(c)

Citizenship:

Switzerland

   

(d)

Title of Class of Securities:

Common Stock, par value $0.001 per share

   

(e)

CUSIP Number:

23282W 10 0

   

Item 3.

If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a(n):

   

(a)

[     ] 

Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o)

 

 

 

(b)

[     ] 

Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c)

 

 

 

(c)

[     ] 

Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c)

 

 

 

(d)

[     ] 

Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8)

 

 

 

(e)

[     ] 

Investment adviser in accordance with §240.13d-1(b)(1)(ii)(E)

 

 

 

(f)

[     ] 

Employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F)

 

 

 

(g)

[     ] 

Parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G)

 

 

 

(h)

[     ] 

Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813)

     

(i)

[     ] 

Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3)

 

 

 

 

(j)

[     ] 

Group in accordance with §240.13d-1(b)(1)(ii)(J)

 

 


 

Item 4.

Ownership

   

(a)

Amount Beneficially Owned:

See response to Item 9 on the cover page.

(b)

Percent of Class:

See response to Item 11 on the cover page.

   

(c)

Number of shares as to which the person has:

     
 
(i)
Sole power to vote or to direct the vote:
    See response to Item 5 on the cover page.
     
 
(ii)
Shared power to vote or to direct the vote:
    See response to Item 6 on the cover page.
     
 
(iii)
Sole power to dispose or to direct the disposition of:
    See response to Item 7 on the cover page.
     
 
(iv)
Shared power to dispose or to direct the disposition of:
    See response to Item 8 on the cover page.

                       On May 4, 2004, Credit Suisse First Boston Equity Partners, L.P., Credit Suisse First Boston Equity Partners (Bermuda), L.P., Credit Suisse First Boston U.S. Executive Advisors, L.P., EMA Partners Fund 2000, L.P. and EMA Private Equity Fund 2000, L.P. (collectively, the "Credit Suisse Entities"), entered into a Voting Trust Agreement with Wells Fargo Bank, N.A. (the "Trustee") (the "Voting Trust Agreement"), pursuant to which, among other things, the Credit Suisse Entities deposited 1,765,683 shares of Common Stock (representing 4.1% of the outstanding shares of Common Stock as of December 31, 2006) (the "Trustee Shares") into a trust created by the Voting Trust Agreement and gave the Trustee the exclusive right to vote the Trustee Shares. The Trustee is the record holder of the Trustee Shares and the Credit Suisse Entities hold trust certificates representing the Trustee Shares. While the Trustee has the exclusive right to vote the Trustee Shares, the Credit Suisse Entities maintained and continue to have dispositive power over the Trustee Shares.

Item 5.

Ownership of Five Percent or Less of a Class

 

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [     ] 

 

 

 

 

Item 6.

Ownership of More than Five Percent on Behalf of Another Person

Not Applicable.

 

 

 

 



 

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company

See Schedule I.

Item 8.

Identification and Classification of Members of the Group

Not Applicable.

Item 9.

Notice of Dissolution of Group

Not Applicable.

Item 10.

Certification

Not Applicable.

 

 

 

 

 

 

 

 



 

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

February 14, 2007

 

  CREDIT SUISSE
     
  By:      /s/ Ivy Dodes              
  Name:      Ivy Dodes
  Title:      Managing Director

 

 

 

 

 

 

 



 

 

Schedule I

 

In accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998), this Schedule 13G/A is being filed by Credit Suisse (the “Bank”), a Swiss bank, on behalf of its subsidiaries to the extent that they constitute the Investment Banking division (the “Investment Banking division”), the Alternative Investments business (the “AI Business”) within the Asset Management division (the “Asset Management division”) and the U.S. private client services business (the “U.S. PCS Business”) within the Private Banking division (the “Private Banking division”) (the “Reporting Person”). The address of the Bank’s principal business and office is Uetlibergstrasse 231, P.O. Box 900, CH 8070 Zurich, Switzerland. The address of the Reporting Person’s principal business and office in the United States is Eleven Madison Avenue, New York, New York 10010.

The ultimate parent company of the Bank is Credit Suisse Group (“CSG”), a corporation formed under the laws of Switzerland. CSG is a global financial services company, active in all major financial centers and providing a comprehensive range of banking products. The Bank is comprised of the Investment Banking division, the Asset Management division and the Private Banking division. The Investment Banking division provides financial advisory and capital raising services and sales and trading to institutional, corporate and government clients worldwide. The Asset Management division provides asset management and investment advisory services to institutional, mutual fund and private investors worldwide and offers products across a broad range of investment classes, including alternative investments. The Private Banking division offers global private banking and corporate and retail banking services in Switzerland. CSG’s business address is Paradeplatz 8, P.O. Box 1, CH 8070 Zurich, Switzerland.

CSG, for purposes of the federal securities laws, may be deemed ultimately to control the Bank and the Reporting Person. CSG, its executive officers and directors, and its direct and indirect subsidiaries (including those subsidiaries that constitute the Asset Management division (other than the AI Business) (the “Traditional AM Business”) and the Private Banking division (other than the U.S. PCS Business) (the “Non-U.S. PB Business”)) may beneficially own securities to which this Schedule 13G/A relates (the “Shares”) and such Shares are not reported in this Schedule 13G/A. CSG disclaims beneficial ownership of Shares beneficially owned by its direct and indirect subsidiaries, including the Reporting Person. Each of the Traditional AM Business and the Non-U.S. PB Business disclaims beneficial ownership of Shares beneficially owned by the Reporting Person. The Reporting Person disclaims beneficial ownership of Shares beneficially owned by CSG, the Traditional AM Business and the Non-U.S. PB Business.